UCB presented data from a Phase 1b study of UCB0599, an oral compound that suppresses alpha-synuclein misfolding, at the American Association of Neurology meeting in April.
The misfolding of alpha-synuclein occurs early in the cascade of pathological events that lead to the development of Parkinson’s disease. In preclinical studies, UCB0599 was shown to suppress this early misfolding. Importantly, UCB0599 is able to cross the blood-brain barrier, a significant hurdle for therapies that target the brain.
The Phase 1b study demonstrated that UCB0599 was well-tolerated in a group of adults with mild to moderate Parkinson’s disease. UCB is now enrolling patients with early-stage Parkinson’s in its Phase 2 ORCHESTRA trial, which is expected to finish in October 2023.
